News

Filter

Current filters:

DermatologicalsPfizer

1 to 9 of 10 results

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

Pfizer sees mixed top-line results in the first two of five phase III clinical trials of tofacitinib

09-10-2013

Pfizer has announced mixed top-line results from two Phase III clinical trials of tofacitinib for the…

DermatologicalsNorth AmericaPfizerPharmaceuticalResearchtofacitinibXeljanz

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Pfizer to buy Excaliard, gaining rights to Ph II skin scarring product

23-11-2011

Global pharma behemoth Pfizer (NYSE: PFE) says it has entered into a definitive agreement to acquire…

DermatologicalsExcaliard PharmaIsis PharmaceuticalsMergers & AcquisitionsPfizerPharmaceutical

46% of US dermatologists expect to prescribe Pfizer’s tofacitinib to psoriasis patients who failed one biologic

17-11-2011

In the first year following its approval for psoriasis, nearly one-half (46%) of surveyed dermatologists…

apremilastCelgeneDermatologicalsMarkets & MarketingNorth AmericaPfizerPharmaceuticaltofacitinib

Many European dermatologists want more post-marketing data before Rxing Pfizer’s Janus

12-09-2011

At least half of surveyed dermatologists across the EU5 (France, Germany, Italy, Spain and the UK) will…

BiotechnologyDermatologicalsEuropeJanusMarkets & MarketingPfizerPharmaceuticaltofacitinib

1 to 9 of 10 results

Back to top